Introduction
The most common metastatic site for breast carcinoma is bone (1, 2) . The development of metastatic bone disease (MBD) in breast cancer (BrCa) is associated with morbidity and skeletal related events (SREs), including pathological fractures, spinal cord compression, hypercalcemia and bone pain (2) . Established MBD is considered an incurable disease and the current therapeutic options include palliation and prevention of SREs. MBD is predominantly osteolytic in BrCa, but it is also infrequently associated with osteoblastic lesions (3) there is a need for alternative bone agents with a better tolerability profile and perhaps greater efficacy in reduction of SREs and disease reoccurrence.
Cathepsin K (CatK), a lysosomal cysteine protease, is expressed predominantly in OCs (9) .
CatK degrades type I collagen by cleaving the triple helical domains at multiple sites and directly releasing the telopeptides (10). Modulation of CatK activity by small molecule inhibitors reduces bone resorption activity of OCs in vitro and in vivo (11, 12) . In preclinical models of estrogendeficiency induced bone loss, multiple CatK inhibitors have been demonstrated to effectively prevent loss of bone mineral density, increase cortical thickness and improve bone strength in ovariectomized (OVX) rodents, rabbits and monkeys (11). Expression of CatK mRNA or protein has been reported in breast and prostate cancers (13, 14) . Le Gall et al previously reported the expression of CatK in breast tumors and its expression is further increased in BrCa cells that metastasize to bone (15) ,. In that study, a preclinical model of skeletal metastasis utilized the intratibially implanted CatK expressing human BT474 BrCa cells in nude mice, and intraperitoneal dosing of the CatK inhibitor (CatKi) AFG-495 was shown to reduce osteolytic lesions and skeletal tumor burden (15) .
The selective CatKi odanacatib (ODN) is currently in large phase III fracture prevention trials as an orally active 50mg once-weekly drug for the treatment of postmenopausal women and men with osteoporosis (12) . Recently, ODN was also evaluated in a small clinical study involving breast cancer patients with established metastatic bone disease, who received either ODN (5mg, once-daily) or zoledronic acid (ZOL, a single intravenous infusion of 4mg) for 4 weeks of treatment. ODN suppressed the bone resorption marker, urinary N-telopeptide similarly to ZOL (16) Because of the species differences between the rat/mouse CatK (87-88% homology) and human CatK enzyme, ODN displays a low potency against the rodent enzyme. To further our understanding on the potential benefits and mechanisms of the CatK inhibitors compared to the bisphosphonates for the treatment of MBD, we selected L-006235 (L-235) as a proof-of-concept CatKi for evaluation in various rodent models of metastatic disease. The reversible CatKi, L-235, is structurally related to ODN (17, 18) . This compound inhibits human CatK with a Ki of 0.25 nM, and is >4000-fold selective against other human cathepsins L, B and S (17) . However, unlike ODN, L-235 shows relatively good potency against mouse (IC 50 =20nM) and rat (IC 50 =12nM)
CatK activity (19, 20) . Efficacy of L-235 as a bone resorption inhibitor has been well established in rabbits, it inhibits rabbit CatK (IC 50 =0.5nM) and bone resorption in vitro by rabbit OCs (IC 50 =5nM) (17) . When dosed orally once-daily for 27 weeks in ovariectomized-rabbits, L-235 at 10mg/kg prevented estrogen deficiency-induced osteopenia (21) . Hence, the aim of this study was to evaluate the efficacy of L-235 as a preclinical proof-of-concept CatKi, compared to ZOL in the prevention and treatment of osteolysis and skeletal tumor progression and local metastasis in the Transcriptase, at 25°C for 10 min, 48°C for 30 min and 95°C for 5 min. Primers and fluorogenic probes for CatK were designed using Primer Express v.1.0 (Applied Biosystems, CA) using the forward primer (5′-CTGGCTATGAACCACCTGGG-3′), reverse primer (5′-TGCGGGAATGAGA CAGGG-3′) and fluorogenic probe (5'-AAGAGGTGGTTCAGAAGATGACTGGACTCAAAGT A-3'). GAPDH primers and fluorogenic probes were from Applied Biosystems with the fluorescent reporter dye FAM (6-carboxy-fluorescein) at the 5'-end and the quencher dye TAMRA (6-carboxytetramethyl-rhodamine) at the 3'-end. Real-time PCR (50μL) included 10μL of RT product (50ng total RNA), 100nM forward-primer, 100nM reverse-primer, 200nM probe and 1× Universal Master Mix (Applied Biosystems) for 2 min at 50°C, 10 min at 95°C followed by 40 cycles at 95°C for 15 sec, 60°C for 1 min. All reactions were performed in ABI Prism 7700 Sequence Detection System. Expression levels of mRNA were expressed relative to GAPDH. heat-inactivated FBS, 2mM glutamine, 100U/ml penicillin-G sodium, 100μg/ml streptomycin sulfate, 0.25μg/ml amphotericin B and 25μg/ml gentamicin at 37°C and 5% CO 2 . The cell proliferation and invasion assays were done essentially as previously described (15) . were monitored on a daily basis for the first week, and then switched to weekly basis until the study ended. Animals were sacrificed on day-42 and the hind limbs were harvested and fixed in 10% buffered formalin for histological analyses and μCT imaging.
To monitor osteolysis on days 0, 7, 14, 21, 28 and 35, the rats were sedated, anesthetized and subjected to digital x-ray imaging of the mid region of the hindlimbs using a Faxitron MX-20 (Field Emission Co.) with a 3sec exposure time on calibrated settings (~25 kV). A fixed square 100x100 pixel region of interest (ROI) within the proximal tibial image was processed for pixel intensity on a scale of 0-255 using Image Tool Processing Kit 3.0 plug-in filters. The average pixel intensity was computed over the entire ROI for each tibia image. microscope equipped with a Spot Slider digital camera (Diagnostic Instruments, Sterling Heights, MI) and saved as JPEG files. From these images, areas of tumor and bone were evaluated using Image Pro imaging software (Media Cybernetics, Silver Spring, MD). Areas for "solid" and "infiltrated" tumor were drawn manually. Extraskeletal tumor area outside of the bone cortical envelope was also contoured.
To evaluate the effect of ZOL and the CatKi on cortical bone, the degree of cortical disruption was evaluated in H&E stained sagittal sections by manually tracing the gaps or disrupted lengths of cortical bone of the proximal tibia (10mm length from the growth plate) using ImagePro software. Cortical disruption (%) was determined from the ratio of lengths of cortical gaps to total length of two cortical surfaces.
To determine distal metastases within tibial marrow and away from the original injected site, the slides were scanned on a Hewlett Packard Scanjet 8200 flatbed scanner (Hewlett Packard, Houston, TX) and imported into Image Pro. Distal tumor tissue was identified along the marrow of the tibial shaft. Matching the microscopic observation with the scanned image, the distance from the growth plate to the most distal tumor tissue was measured using the Image Pro software.
Statistical Analysis -All data were analyzed with StatView software (version 5.0; SAS Institute, Inc.). Statistical analyses were carried out by unpaired Student's t-test or ANOVA, followed by a Fisher's protected least significant difference test. P<0.05 were considered statistically significant. 
Results

Expression of Cathepsin K in Breast Cancer
The BrCa tissue microarray (TMA) slides contained malignant and non-malignant breast tumor samples from 88 patients diagnosed with breast ductal carcinoma. The tissue array grading included breast biopsies from: 49 patients with primary breast tumor who had no regional lymph node metastasis and no distal metastasis (N=0, M=0), 27 patients with metastasis in 1 or more regional lymph nodes without distal metastasis (N≥1, M=0), and 12 patients with lymph node involvement as well as presence of distal metastasis (M>0). As shown in Figure 1 , high CatK expression was specifically detected in the epithelial cells of breast ductal carcinoma, while the surrounding basal cells showed little to no expression of this protease (Fig. 1A) . At high magnification, CatK was localized in the cytoplasm and with punctate appearance (Fig. 1A-d ).
Approximately 40% of breast tumor tissue biopsies surveyed were positive for CatK expression (42-48%) regardless of TMN grade in BrCa severity (Table 1) .
We also correlated CatK mRNA levels in human metastatic ductal carcinoma (Fig. 1B) .
Note, each matched pair was from the same donor. The primary pairs (n=12) consisted of primary breast tumor and adjacent normal tissue while the metastatic pairs (n=4) consisted of primary breast tumor and corresponding metastatic tissue. CatK expression was frequently upregulated (7 of 12 samples) in primary tumors versus the respective adjacent normal tissue (Fig. 1B-a) . Primary tumor tissue demonstrated a 55% increase (p<0.05) in CatK expression as compared to normal adjacent tissue (Fig 1B-a) . CatK mRNA level was more dramatically increased when comparing primary tumor to that in metastatic tissue (Fig. 1B, b) . CatK mRNA in metastatic tissue was elevated ~3-fold (p<0.05) as compared to its matched primary tumor in all 4 donors (Fig 1B-b) . 
Cathepsin K inhibitor reduced osteolysis in an experimental model of human BrCa metastasis
We conducted two different studies that included dose ranging of L-235, comparing to ZOL, in prevention (dosing began day-1) or treatment mode (dosing started day-7 post-injection). The structure of L-235 is shown in Figure 2A . L-235 orally dosed at 10, 30 and 100mg/kg twice daily provided mean plasma exposure levels of 10.4, 35.6 and 166.2μM•hr, respectively. ZOL was subcutaneously dosed at 7.5μg/kg weekly. For both studies, there were no treatment-related adverse effects observed. There were no differences in body weights of animals treated with either L-235 or ZOL as compared to vehicle treated controls over the study duration of 42-days (data not shown).
Progression of osteolytic lesions was followed by Faxitron analysis and quantified every week up to day-35 as bone density (mean pixel intensity). In the prevention regimen, bone density measurements showed significant osteolysis in vehicle controls at day-7, -21 and -35 post-injection ( Fig. 2B-a) , while treatment with ZOL and L-235 protected against focal osteolysis (Fig. 2B-b&c) .
From density measurements within a defined ROI in the proximal tibia, the vehicle controls showed -3.3% change from baseline intensity measured at day 0. L-235, 10, 30 and 100mg/kg, bid, resulted in -2.5, 6.5 and 9.5% change in bone density at day-35 vs. baseline. ZOL at 7.5 μg/kg (s.c., weekly) showed comparable efficacy to L-235 100mg/kg (p.o., b.i.d.) with a 9.5% increase in bone pixel density (p<0.05). In the treatment regimen, vehicle-treated animals showed -5.9% change of bone density vs. baseline, while L-235 30mg/kg and ZOL increased bone density 1.9 and 7.3% respectively.
To obtain a more sensitive measurement of osteolysis, bone volume/total tissue volume (BV/TV) was evaluated from proximal tibia post-necropsy (day-42) by ex-vivo μCT. Note, BV/TV (%) is expressed relative to that of age matched intact nude rats. In the prevention regimen ( 2C, a), BV/TV of vehicle-treated proximal tibia was 61%, while the ZOL-treated tibia was 86% of intact controls. L-235 dose dependently reduced osteolysis, with BV/TV of 72, 75 and 87% of intact controls, respectively. Similar results were obtained in the treatment experiment (Fig. 2C-b) , where osteolysis was significantly inhibited by either ZOL or L-235 30mg/kg, resulting in BV/TV of 101% and 80% respectively, significantly above vehicle.
Characterization of tumor growth post-intratibial injection
To evaluate the effects of the CatKi and ZOL on tumor progression, sagittal sections of the tibia from vehicle were subjected to immunohistochemical staining for cytokeratin to visualize the BrCa tumor cells (Fig. 3A-a) . The tibial medullary space contained areas of normal bone marrow and intratibial solid tumor mass originating from the injection site of MDA-MB231 cells, and led to aggressive trabecular osteolysis. Extraskeletal tumor mass was also detected outside of the cortical envelope and in contact with the surrounding soft tissue. Abundant TRAP-positive OCs were recruited to endosteal (Fig. 3A-b) and periosteal (Fig. 3A-c) cortical surfaces, as well as trabecular surfaces (data not shown) in proximity to tumor cells. In addition, cytokeratin positive cells were also detected in the bone marrow space distant from the solid tumor mass. We characterized the positive cellular mass as "solid" and "infiltrated" tumor and micrometastasis. Solid tumor was characterized by a solid mass of tumor cells with no bone within the mass, while the "infiltrated" tumor area represented BrCa cells growing amongst the trabecular bone and into the surrounding bone marrow space (Fig. 3A-d) . It should be noted that the infiltrated tumor area included some degree of host fibroblastic tissue as demonstrated by cytokeratin staining. Interestingly, small discrete micrometastases were frequently detected toward the distal tibia, a site distant from the (Fig. 3A-e) . Using the growth plate as a consistent landmark, we suggest that the distance to the micrometastasis from the landmark site represented the invasive activity of MDA-MB-231 BrCa tumor cells.
To further characterize the observations in cytokeratin-stained sections, measurements on tumor areas were determined from the H&E stained tibial sections from vehicle, ZOL and L-235 treated rats as described in Figure 3B (a-c) . We examined treatment-related effects on BrCa tumor growth within the tibia at higher magnification (Fig. 3B, d-f) . Tumor growth was extensively detected in the vechicle treated tibia, even at the site distal from the injected site ( Fig. 3B-d , same region as the white box in Fig. 3B-a) . ZOL treatment resulted in protection of trabecular and cortical structures in the BrCa cell injected tibia (Fig. 3B-b) ; however, tumor (T) cell growth were found to infiltrate among the trabeculae (Fig. 3B-e , same region as the white box in Fig. 3B-b) . L-235 treatment protected both trabecular and cortical structures, and significantly reduced BrCa tumor cell infiltration even at a site proximal to the injected site (Fig. 3B-f , same region as the white box in Fig. 3B-c) . The parameters described in the following sections, were determined using image analyses, including the intratibial solid tumor area, extraskeletal tumor area, infiltrated tumor area and distance to micrometastasis.
Cathepsin K inhibitor protected against cortical disruption
The data on cortical integrity is expressed here as the percent of the combined length of the eroded cortex for the anterior and posterior cortical surfaces to the total cortical length. When the tibial cortical envelope was completely disrupted (Fig. 3B-a) , the cortical length was estimated by image analysis ( Fig. 3B-a; dash lines) . In the prevention study, ~70% of the cortical bone was eroded in untreated animals. L-235 dose-dependently preserved cortical bone and reduced cortical 
disruption to 36, 17 and 11% respectively, versus vehicle, while ZOL resulted in 25% cortical disruption (p<0.05; Fig. 4a ). Similar results were seen in the treatment regimen where L-235 30mg/kg and ZOL showed 31 and 24% cortical disruption, respectively, compared to vehicle that showed 58% cortical disruption (p<0.05; Fig. 4b ). The effects of L-235 versus ZOL on the preservation of cortical bone correlated well with the reduction of tumor burden as described in the section below.
Cathepsin K inhibitor reduced skeletal BrCa tumor burden
Reduction of intratibial BrCa tumor
Extensive tumor growth was evident in the vehicle group in both the prevention ( Fig. 3B-a; Fig. 5A-a) and treatment protocol (Fig. 5A-b) . Treatment with L-235 (up to 10μM) did not change the rate of MDA-MB231 cell proliferation in vitro (data not shown). On the other hand, histological examination of the in vivo study clearly showed that the intratibial tumor burden was significantly reduced by treatment with ZOL ( Fig. 3B-b) or L-235 100mg/kg dose (Fig 3B-c) . In the prevention protocol, the vehicle group showed solid tumor area of 24±1.2mm 2 ( Fig. 5A-a) .
While ZOL potently reduced solid tumor area by more than 85% vs. vehicle, the CatKi at 30 and 100mg/kg markedly reduced solid tumor area by 70-75% vs. vehicle. Similarly, in treatment mode, efficacy of L-235 30mg/kg was comparable to ZOL in reducing solid tumor burden (Fig. 5A-b) .
Intratibial solid tumor volume was also determined from the μCT-based 3-D reconstructed images of the osteolytic void volume (Fig. 5B ). In the prevention study, tumor volume was reduced by treatment with L-235 at 10, 30 and 100mg/kg doses by 29, 40 and 63%, respectively, as compared to ZOL that reduced tumor volume by 56% (Fig. 5B-a) . Similar responses were observed in the treatment experiment where L-235 30mg/kg and ZOL resulted in 37% and 72% reduction of tumor volume, respectively (Fig. 5B-b) .
Reduction of extraskeletal BrCa tumor
Tumor area outside of periosteal surface of the proximal tibia was also measured from the H&E sagittal sections. In the case that the tibial cortical envelope was completely disrupted (Fig.   3B-a) , tumor area was estimated based on the predicted cortical outlines ( Fig. 3B-a; dash lines) . All treatments significantly reduced tumor area outside of the cortical bone envelope (Fig. 6A ). In the prevention study, the CatKi at all doses significantly reduced tumor burden in soft tissue by 60 -80% vs. vehicle, while ZOL resulted in a 68% reduction (Fig. 6A-a) . Similar results were seen in the treatment study where L-235 at 30mg/kg and ZOL reduced tumor area outside of bone by 73% (p<0.05) and 62% (NS), respectively, versus vehicle (Fig 6A-b) .
Cathepsin K inhibitor reduced BrCa local metastasis
Infiltrated tumor
Efficacy of L-235 in inhibiting the BrCa MDA-MB-231 cell invasion in vitro was evaluated essentially as previously described (15) . This CatKi potently inhibited the BrCa matrigel invasion with an IC 50 of 3.2 nM (data not shown) as compared to its activity in blocking osteoclastic bone resorption (IC 50 = 5 nM) (17) . Therefore, the ability of the intratibially injected MDA-MB-231 cells to invade to sites distant from the original injected site was characterized in vivo by immunohistochemically staining the sections from injected tibia for cytokeratin, a marker of the BrCa cells (Fig 3A-d&e) . ZOL markedly reduced solid tumor area, and protected trabecular and infiltrated the bone marrow among the preserved trabeculae. Small tumors could be detected further down the tibial shaft (Fig. 3B-b) . In contrast, the L-235-treated tibia showed high density of trabecular spicules associated with normal bone marrow integrity (Fig 3B-c) . The "infiltrated" tumor area was determined by measuring the total tumor-containing trabecular area and subtracting out the trabecular bone area. In the prevention protocol (Fig. 6B, a) , the majority of tumor burden in vehicle-treated animals was solid tumor (24.1±1.2mm (Fig. 6B-b) .
Local Metastasis
Based on our examination of the tibial sections stained with cytokeratin, small discrete tumor areas were detected toward the distal tibial end. Since bone marrow is known for high vascularization activity, we believe these small islands of BrCa cells represent local metastatic activity, and thus the distance from growth plate to the most distal site of observable micromass of tumor was determined to assess treatment-related effects on local metastasis. In the prevention protocol ( Fig. 6C-a 
ODN at 5mg p.o., daily provided mean plasma concentration of 512 ± 203 nM in BrCa patients (16) and due to the relatively short half-life of L-235 in rodent, we thus selected L-235 at 10, 30, and 100mg/kg twice-daily, which provided the mean plasma concentrations of 10. 4 The function of CatK in BrCa is presently unknown. Besides its expression in OCs, there is limited evidence that CatK is also expressed in human breast carcinomas (14, 15) . In addition, BrCa cells residing in bone metastases overproduce CatK relative to the expression levels in primary tumors and soft tissue metastases (15) . These findings suggest that cancer cells metastasizing to bone express bone-related genes to adapt and thrive in the bone microenvironment (29) . We confirmed high expression of CatK in primary BrCa tumors and its upregulation in metastatic tumors as previously reported (15) . To further examine the role of CatK in BrCa metastasis, Le Table 1 Correlation of cathepsin K expression to histological grading of a breast tumor tissue microarray. 
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